rs1611115 — DBH -1021C>T
Strongest known genetic determinant of dopamine beta-hydroxylase activity, controlling the dopamine-to-norepinephrine ratio
Details
- Gene
- DBH
- Chromosome
- 9
- Risk allele
- T
- Consequence
- Regulatory
- Inheritance
- Codominant
- Clinical
- Risk Factor
- Evidence
- Strong
- Chip coverage
- v3 v4 v5
Population Frequency
Ancestry Frequencies
Category
Brain & Mental HealthThe Dopamine-to-Norepinephrine Switch — Why One Variant Controls So Much
Your brain runs on a delicate balance between dopamine11 dopamine
The "motivation and reward" neurotransmitter. Dopamine drives focus,
pleasure-seeking, and motor control. Too much is linked to impulsivity; too little to apathy and
Parkinson's-like symptoms and norepinephrine22 norepinephrine
The "alertness and stress response" neurotransmitter.
Norepinephrine sharpens attention, raises blood pressure, and mobilizes the body for action.
It is synthesized directly from dopamine by the enzyme DBH. The enzyme that converts one into
the other is dopamine beta-hydroxylase (DBH), and the rs1611115 variant in its promoter region
is the single most powerful genetic determinant of how much DBH your body makes. Carriers of the
T allele produce dramatically less enzyme, tilting their neurochemistry toward higher dopamine and
lower norepinephrine — a shift with far-reaching consequences for cognition, stress response,
cardiovascular function, and substance sensitivity.
The Mechanism
The rs1611115 variant sits in the promoter region33 promoter region
The DNA sequence upstream of a gene that
controls when and how much the gene is transcribed into mRNA. Changes here don't alter the
protein itself but control how much protein is made of the DBH gene on chromosome 9,
approximately 1,021 base pairs upstream of the transcription start site. The T allele reduces
transcriptional activity, leading to less DBH mRNA and consequently less enzyme protein.
Allele-specific expression studies44 Allele-specific expression studies
Tang et al. Regulatory Polymorphisms in Human DBH Affect
Peripheral Gene Expression and Sympathetic Activity. Circulation Research,
2014 in human tissues reveal striking effects:
the T allele causes approximately 4-fold lower DBH mRNA expression in the liver, with pronounced
allelic imbalance in all 17 heterozygous liver samples tested. The effect is tissue-specific —
liver and lung show the strongest reductions, while the locus coeruleus55 locus coeruleus
The brain's primary
norepinephrine-producing nucleus, a small cluster of neurons in the brainstem that sends
noradrenergic projections throughout the entire brain and adrenal glands show minimal
allelic imbalance, suggesting compensatory mechanisms in the central nervous system.
DBH is a copper-dependent oxygenase66 copper-dependent oxygenase
DBH requires two copper ions per subunit and uses
molecular oxygen and ascorbic acid (vitamin C) as co-substrates. Without adequate copper
or vitamin C, the enzyme cannot function efficiently regardless of genotype that requires
both copper and vitamin C (ascorbic acid) as essential cofactors. This biochemistry makes
these nutrients directly actionable for T-allele carriers.
The Evidence
The foundational study by
Zabetian et al.77 Zabetian et al.
Zabetian CP et al. A quantitative-trait analysis of human plasma-dopamine
beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus.
Am J Hum Genet, 2001 measured plasma DBH activity
across 522 individuals from three populations. The results were dramatic: among European
Americans, TT homozygotes had mean enzyme activity of just 4.1 nmol/min/ml compared with
48.1 for CC homozygotes — a nearly 12-fold difference. CT heterozygotes fell in between at
25.2. The variant explained 35% of activity variance in African Americans and 51-52% in
European Americans and Japanese, making it one of the strongest single-SNP effects on any
measurable human phenotype.
The clinical consequences of this enzyme variation span multiple domains:
Cognition and ADHD: Low DBH activity has been repeatedly associated with attention-deficit
traits.
A study in Eastern Indian ADHD patients88 A study in Eastern Indian ADHD patients
Bhaduri N, Bhattacharyya M. Study on DBH Genetic
Polymorphisms and Plasma Activity in Attention Deficit Hyperactivity Disorder Patients from
Eastern India. Cell Mol Neurobiol, 2009 found
strong correlation between rs1611115 genotype and plasma DBH activity (P = 1.51 x 10-6),
and the T allele has been linked to increased impulsiveness and aggression in multiple studies.
Alzheimer's disease: The
Epistasis Project99 Epistasis Project
Combarros O et al. The dopamine beta-hydroxylase -1021C/T polymorphism
is associated with the risk of Alzheimer's disease in the Epistasis Project. BMC Med Genet,
2010 found the T allele associated with AD
risk (OR = 1.2, P = 0.005) across 1,757 cases and 6,294 controls, with a particularly
strong effect in men under 75 (OR = 2.2). This association showed epistasis with the
inflammatory gene IL1A, suggesting that low DBH activity may impair the regulation of
neuroinflammation.
Cardiovascular effects: Paradoxically, while the T allele appears to increase neurological risk, it shows a protective cardiovascular profile. Tang et al. found the T allele associated with reduced risk of angina pectoris (OR = 0.43, P = 0.0002) and possibly myocardial infarction across three independent cohorts totaling over 9,000 subjects. Males homozygous for the C allele (high DBH) showed significantly higher myocardial contractility under stress, consistent with greater sympathetic drive.
Substance sensitivity: A
pharmacogenetic trial1010 pharmacogenetic trial
Kosten TR et al. Pharmacogenetic randomized trial for cocaine
abuse: disulfiram and dopamine beta-hydroxylase. Biol Psychiatry,
2013 demonstrated that disulfiram (which
inhibits DBH) reduced cocaine-positive urines only in CC genotype patients, while CT and
TT carriers — who already have low DBH — showed no benefit. The T allele has also been
associated with alcohol withdrawal seizures and delirium tremens risk.
Practical Implications
The DBH enzyme requires copper and vitamin C as cofactors, making nutritional support a direct intervention for T-allele carriers. Ensuring adequate intake of both nutrients helps maximize whatever enzyme activity the genotype allows.
Carriers of the T allele operate with a higher dopamine-to-norepinephrine ratio, which can manifest as enhanced creativity and reward sensitivity but also as difficulty sustaining attention, increased stress reactivity, and vulnerability to orthostatic symptoms (feeling dizzy when standing quickly). These are not pathological in most people but represent a different neurochemical set point that benefits from awareness and management.
For cardiovascular health, the T allele may actually be protective — lower sympathetic drive means less cardiac stress. But for brain health and cognitive function, supporting DBH activity through nutrition and lifestyle becomes more important with age, given the Alzheimer's association.
Interactions
DBH rs1611115 interacts with other variants in the DBH gene itself. The coding variant rs6271 (+1603C>T, Arg535Cys) independently reduces enzyme activity, and together with rs1611115 and rs2519152, these three variants explain up to 37.6% of plasma DBH variance in African Americans.
The catecholamine pathway involves several genes that may interact with DBH status. COMT (rs4680) controls dopamine degradation — a person with both low DBH (rs1611115 TT) and slow COMT (Val158Met, Met/Met) would have a doubly-shifted dopamine balance: less conversion to norepinephrine and slower clearance of existing dopamine. This combination may amplify both the cognitive benefits and the stress vulnerability of elevated dopamine.
The Alzheimer's-related epistasis between DBH rs1611115-T and IL1A -889TT (rs1800587) suggests that the neuroinflammatory consequences of low norepinephrine may depend on inflammatory gene background, a finding that warrants further investigation.
Nutrient Interactions
Genotype Interpretations
What each possible genotype means for this variant:
Normal dopamine beta-hydroxylase activity with typical dopamine-to-norepinephrine conversion
The CC genotype at rs1611115 produces the highest levels of DBH enzyme expression and activity. In the landmark Zabetian et al. 2001 study, CC individuals averaged 48.1 nmol/min/ml plasma DBH activity in European Americans and 39.0 in African Americans. This means your sympathetic nervous system operates at full capacity for norepinephrine synthesis.
Interestingly, the high-activity CC genotype has been associated with greater myocardial contractility under stress in males, reflecting higher sympathetic drive. While this is normal physiology, it means CC carriers may be more responsive to stress-induced cardiovascular changes. The Tang et al. 2014 study also found that the CC genotype was associated with slightly higher risk of angina compared to T-allele carriers, though this needs to be interpreted in the context of overall cardiovascular health.
Moderately reduced DBH activity (~50% of normal) with shifted dopamine-to-norepinephrine ratio
Heterozygous CT carriers show a clear intermediate phenotype that reflects the codominant nature of this variant. The T allele reduces DBH promoter activity by approximately 4-fold in liver tissue, and with one functional C allele and one reduced T allele, you produce roughly half the enzyme of a CC individual.
The Epistasis Project found that even one T allele was associated with modestly increased Alzheimer's risk (the overall OR of 1.2 was for T-allele presence in either heterozygous or homozygous form). However, the cardiovascular profile of T-allele carriers tends to be favorable, with reduced risk of angina (OR = 0.43 for T-allele carriers in the Tang et al. 2014 study).
Because DBH requires copper and ascorbic acid as cofactors, ensuring adequate intake of these nutrients can help maximize your remaining enzyme capacity. This is a straightforward nutritional optimization rather than a medical intervention.
Significantly reduced DBH activity (~10% of normal) with markedly elevated dopamine-to-norepinephrine ratio
The TT genotype produces dramatically reduced DBH enzyme activity across all populations studied. In the Zabetian et al. 2001 study, TT individuals averaged only 4.1 nmol/min/ml in European Americans (vs. 48.1 for CC) and 6.0 in African Americans (vs. 39.0 for CC). One Japanese TT individual had activity of just 0.4 nmol/min/ml.
This near-absence of plasma DBH activity means your body converts very little dopamine to norepinephrine, resulting in relatively high dopamine and low norepinephrine levels. The consequences are multi-system:
Cognitively, the high dopamine state may enhance certain functions (creativity, reward processing) while impairing others (sustained attention, working memory under stress). The association with ADHD traits and impulsiveness has been documented in multiple populations.
The Alzheimer's risk association is strongest for TT carriers, particularly men under 75. The proposed mechanism involves the loss of noradrenergic neuroprotection — norepinephrine normally suppresses neuroinflammation in the brain, and reduced production may leave the brain more vulnerable to inflammatory damage with aging.
Cardiovascularly, TT carriers actually show a protective profile with lower sympathetic drive and reduced risk of angina, as demonstrated across multiple cohorts.
Importantly, DBH requires copper and vitamin C as obligate cofactors. For TT carriers, optimizing these nutrients is especially valuable because you need every bit of enzyme capacity your genotype can provide.
Key References
Zabetian et al. 2001 — landmark study identifying -1021C>T as accounting for 35-52% of plasma DBH activity variance across European American, African American, and Japanese populations (N=522)
Tang et al. 2014 — demonstrated rs1611115-T causes ~4-fold reduction in liver DBH mRNA expression; minor alleles protective against angina (OR=0.43) and possibly MI across 3 cohorts (N=9,440)
Combarros et al. 2010 — Epistasis Project found -1021T associated with Alzheimer's disease (OR=1.2, p=0.005) especially in men <75y (OR=2.2), with IL1A epistasis (N=8,051)
Kosten et al. 2013 — pharmacogenetic trial showing disulfiram efficacy for cocaine dependence is DBH genotype-dependent; CC genotype responded, CT/TT did not (N=74)
Gonzalez-Lopez & Vrana 2019 — comprehensive review of DBH genetic variants in health and disease covering ADHD, PD, AD, PTSD, substance use, and cardiovascular conditions
Bhaduri & Bhattacharyya 2009 — study in Eastern Indian ADHD patients showing strong correlation between rs1611115 and plasma DBH activity (P=1.51E-6) (N=111)
Kang et al. 2018 — meta-analysis of 5 case-control studies found no significant association between rs1611115 and Parkinson's disease risk (N=7,468)